Jun 30, 2023

Semler Scientific Q2 2023 Earnings Report

Semler Scientific reported record quarterly revenues and pre-tax net income, driven by sales of QuantaFlo® for peripheral arterial disease testing. The company is focused on developing its business in heart dysfunction.

Key Takeaways

Semler Scientific reported a 25% increase in revenue to $18.6 million and a 44% increase in net income to $5.9 million for Q2 2023 compared to the corresponding period in 2022. The company achieved record quarterly revenues and pre-tax net income, primarily from sales of QuantaFlo®.

Revenue was $18.6 million, an increase of 25% compared to the corresponding period of 2022

Net income was $5.9 million, an increase of 44% compared to the corresponding period of 2022

Cash, cash equivalents and short-term investments of $51.8 million

Highest quarterly revenues and pre-tax net income since inception

Total Revenue
$18.6M
Previous year: $14.8M
+25.5%
EPS
$0.75
Previous year: $0.51
+47.1%
Gross Profit
$17.4M
Previous year: $13.9M
+25.4%
Cash and Equivalents
$39.5M
Previous year: $40M
-1.3%
Free Cash Flow
$11M
Previous year: $6.09M
+81.0%
Total Assets
$75.5M
Previous year: $57.6M
+30.9%

Semler Scientific

Semler Scientific

Forward Guidance

This press release contains forward-looking statements regarding the development of business in heart dysfunction and diabetes, continued testing of asymptomatic patients, and the benefits of early identification of at-risk patients.